Antidepressant action of ketamine via mTOR is mediated by inhibition of nitrergic Rheb degradation

75Citations
Citations of this article
143Readers
Mendeley users who have this article in their library.
Get full text

Abstract

As traditional antidepressants act only after weeks/months, the discovery that ketamine, an antagonist of glutamate/N-methyl-d-aspartate (NMDA) receptors, elicits antidepressant actions in hours has been transformative. Its mechanism of action has been elusive, though enhanced mammalian target of rapamycin (mTOR) signaling is a major feature. We report a novel signaling pathway wherein NMDA receptor activation stimulates generation of nitric oxide (NO), which S-nitrosylates glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Nitrosylated GAPDH complexes with the ubiquitin-E3-ligase Siah1 and Rheb, a small G protein that activates mTOR. Siah1 degrades Rheb leading to reduced mTOR signaling, while ketamine, conversely, stabilizes Rheb that enhances mTOR signaling. Drugs selectively targeting components of this pathway may offer novel approaches to the treatment of depression.

Cite

CITATION STYLE

APA

Harraz, M. M., Tyagi, R., Cortés, P., & Snyder, S. H. (2016). Antidepressant action of ketamine via mTOR is mediated by inhibition of nitrergic Rheb degradation. Molecular Psychiatry, 21(3), 313–319. https://doi.org/10.1038/mp.2015.211

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free